A Phase I-II Study of R115777 (Tipifarnib, Zarnestra) Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Stage IIB-IIIC Breast Cancer.

Trial Profile

A Phase I-II Study of R115777 (Tipifarnib, Zarnestra) Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Stage IIB-IIIC Breast Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 May 2015

At a glance

  • Drugs Tipifarnib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record..
    • 08 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Sep 2009 Planned number of patients changed from 97 to 86 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top